Effects of sialidase NEU1 siRNA on proliferation, apoptosis, and invasion in human ovarian cancer-OVCAR3 cell
-
摘要: 目的 探讨唾液酸酶1(neuraminidase,NEU1)小干扰RNA (siRNA)对人卵巢癌细胞增殖、凋亡和侵袭的影响。 方法 将人类卵巢癌细胞OVCAR3接种于无抗生素的培养基后进行NEU1 RNA沉默处理。对照组转染加入250 μl Opti-mem无血清培养基,模型组(MOCK)转染加入245 μl Opti-mem无血清培养基和5 μl MOCK siRNA (100 pmol),实验组转染加入245 μl Opti-mem无血清培养基和5 μl NEU1 siRNA (100 pmol)。处理48 h后,收集被转染的细胞,并进行免疫印迹,细胞增殖、细胞周期、细胞凋亡和细胞侵袭试验。 结果 细胞增殖试验和凋亡试验(流式细胞术)结果表明,与模型组相比,NEU1 siRNA能有效抑制癌细胞增殖,阻滞细胞周期G0/G1期,并且诱导细胞凋亡。Transwell实验的结果表明,经NEU1 siRNA处理过的OVCAR3细胞侵袭力被显著抑制。此外,Western blot结果表明NEU1 siRNA可抑制Cln3和Cln5的表达以及降低ATP5B和ATP5J的表达水平。 结论 NEU1 siRNA能有效抑制人类卵巢癌OVCAR3细胞的增殖、凋亡和侵袭,为卵巢癌的靶向治疗提供了一个新方向。Abstract: Objective To elucidate the role of NEU1 siRNA on proliferation, apoptosis, and invasion of OVCAR3 cells. Methods The OVCAR3 cells were transfected with siRNA that knockdown of NEU1. The transfect dye solution preparation for control is about 250 μl Opti-mem serum-free medium, and MOCK group or interfere group were to add 5 μl MOCK siRNA (100 pmol) or NEU1 siRNA (100 pmol) to 245 μl Opti-mem serum-free medium. After 48 h, the transfected cells were collected and processed for Western blot, proliferation, cell cycle, apoptosis, and invasion assay. Results Cell viability assay and flow cytometry showed that NEU1 siRNA effectively inhibited the cancer proliferation, arrested cells cycle at G0/G1 phase, and induced apoptosis when compared to the Mock group. Transwell assay showed that invasion of cells in OVCAR3 treated with NEU1 siRNA were suppressed significantly. In addition, Western blot revealed that expressions of Cln3 and Cln5 were depressed, and ATP5B and ATP5J expressions were also reduced. Conclusion NEU1 siRNA can effectively inhibit proliferation, apoptosis, and invasion of human ovarian cancer cells by targeting lysosome and oxidative phosphorylation signaling, which can serve as a new target ovarian cancer treatment.
-
Key words:
- NEU1 /
- Ovarian cancer /
- Proliferation /
- Apoptosis /
- Invasion
点击查看大图
计量
- 文章访问数: 329
- HTML全文浏览量: 38
- PDF下载量: 0
- 被引次数: 0